companies astrazeneca-plc 
Law 360 M&A
MARCH 19, 2024
AstraZeneca PLC said Tuesday that it will buy Fusion Pharmaceuticals, a biopharmaceutical company specializing in oncology, for up to $2.4 billion in cash to help it transform cancer treatments.
Benzinga
MARCH 14, 2024
Thursday, AstraZeneca Plc (NASDAQ: AZN ) agreed to acquire Amolyt Pharma , a clinical-stage biotechnology company focused on developing treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Law 360 M&A
JANUARY 23, 2023
An investor in biopharmaceutical company CinCor Pharma Inc. billion by European pharmaceutical company AstraZeneca PLC. has alleged there were misrepresentations in a document that detailed a proposed acquisition of CinCor worth up to $1.8
Law 360 M&A
FEBRUARY 8, 2023
stockholders have sued ex-company parent AstraZeneca plc, its UK Ltd. affiliate and key figures of both companies in Delaware's Court of Chancery over a purportedly underpriced, $3 billion sale of Viela that allegedly subordinated its interests to AstraZeneca's pursuit of a bigger deal. Former Viela Bio Inc.
Benzinga
OCTOBER 3, 2022
LogicBio Therapeutics Inc (NASDAQ: LOGC ) shares are trading higher Monday after the company announced it will be acquired by AstraZeneca PLC (NASDAQ: AZN ) subsidiary Alexion for $2.07
IVSC
SEPTEMBER 30, 2022
He is the Chairman of the boards of Stanbic Uganda Holdings Limited (part of Standard Bank Group of South Africa) and Uganda Breweries Ltd (a subsidiary of East African Breweries Plc, part of Diageo Group). Mr.Katto was CEO of Uganda’s Capital Markets Authority (CMA) for 16 years until end of 2013.
Benzinga
AUGUST 4, 2022
AstraZeneca/Merck's Lynparza Scores European Approval In Early Breast Cancer. The FDA recommends the company pursue traditional. Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus. Full story available on Benzinga.com.
Expert insights. Personalized for you.
52 
Let's personalize your content